Last reviewed · How we verify

Remifentanil titration

Ajou University School of Medicine · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Remifentanil titration is a Small molecule drug developed by Ajou University School of Medicine. It is currently FDA-approved.

Remifentanil is a small molecule mu opioid receptor agonist used in the treatment of nociceptive pain. It is typically titrated in a controlled manner to achieve the desired analgesic effect, often guided by monitoring tools such as Nol-Index during procedures like moderate-to-high risk cardiovascular surgery.

At a glance

Generic nameRemifentanil titration
SponsorAjou University School of Medicine
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Remifentanil titration

What is Remifentanil titration?

Remifentanil titration is a Small molecule drug developed by Ajou University School of Medicine.

Who makes Remifentanil titration?

Remifentanil titration is developed and marketed by Ajou University School of Medicine (see full Ajou University School of Medicine pipeline at /company/ajou-university-school-of-medicine).

What development phase is Remifentanil titration in?

Remifentanil titration is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing